Association analysis of GRIN1 and GRIN2B polymorphisms and Parkinson's disease in a hospital-based case-control study

Neuroscience Letters

Volumn 478, Issue 2, 2010, Pages 61-65

  Wu, Shey Lin ^a,b   Wang, Wen Fu ^a   Shyu, Hann Yeh ^c   Ho, Ying Jui ^d   Shieh, Jia Ching ^d   Fu, Yi Ping ^e   Wu, Shwu Tzy ^b   Cheng, Chun Wen ^d,f  

^a CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^b DA YEH UNIVERSITY   (Taiwan)

^c TAOYUAN ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^e UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^f CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

GRIN1; GRIN2B; NMDAR; Parkinson's disease; Single nucleotide polymorphism

Indexed keywords

N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; PROTEIN SUBUNIT;

AGED; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENETIC RISK; GENETIC VARIABILITY; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

ASIAN CONTINENTAL ANCESTRY GROUP; CARRIER PROTEINS; CASE-CONTROL STUDIES; GENETIC ASSOCIATION STUDIES; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HOSPITALS; HUMANS; NERVE TISSUE PROTEINS; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, N-METHYL-D-ASPARTATE; RISK ASSESSMENT; TAIWAN;

EID: 77953620471     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.04.063     Document Type: Article

References (35)

1. Aguiar Pde C., Lessa P.S., Godeiro C., Barsottini O., Felicio A.C., Borges V., Silva S.M., Saba R.A., Ferraz H.B., Moreira-Filho C.A., Andrade L.A. Genetic and environmental findings in early-onset Parkinson's disease Brazilian patients. Mov. Disord. 2008, 23:1228-1233.
2. Allen A.S., Satten G.A. A novel haplotype-sharing approach for genome-wide case-control association studies implicates the calpastatin gene in Parkinson's disease. Gene Epidemiol. 2009, 33:657-667.
3. Anegawa N.J., Lynch D.R., Verdoorn T.A., Pritchett D.B. Transfection of N-methyl-d-aspartate receptors in a nonneuronal cell line leads to cell death. J. Neurochem. 1995, 64:2004-2012.
4. Barzilai A., Melamed E. Molecular mechanisms of selective dopaminergic neuronal death in Parkinson's disease. Trends Mol. Med. 2003, 9:126-132.
5. Begni S., Moraschi S., Bignotti S., Fumagalli F., Rillosi L., Perez J., Gennarelli M. Association between the G1001C polymorphism in the GRIN1 gene promoter region and schizophrenia. Biol. Psychiatry 2003, 53:617-619.
6. Borghammer P., Vafaee M., Ostergaard K., Rodell A., Bailey C., Cumming P. Effect of memantine on CBF and CMRO2 in patients with early Parkinson's disease. Acta Neurol. Scand. 2008, 117:317-323.
7. Chen H.S., Lipton S.A. The chemical biology of clinically tolerated NMDA receptor antagonists. J. Neurochem. 2006, 97:1611-1626.
8. Chiu H.J., Wang Y.C., Liou Y.J., Lai I.C., Chen J.Y. Association analysis of the genetic variants of the N-methyl d-aspartate receptor subunit 2b (NR2b) and treatment-refractory schizophrenia in the Chinese. Neuropsychobiology 2003, 47:178-181.
9. Daniels S. Cellular and neurophysiological effects of high ambient pressure. Undersea Hyperb. Med. 2008, 35:11-19.
10. Edwards T.L., Scott W.K., Almonte C., Burt A., Powell E.H., Beecham G.W., Wang L., Zuchner S., Konidari I., Wang G., Singer C., Nahab F., Scott B., Stajich J.M., Pericak-Vance M., Haines J., Vance J.M., Martin E.R. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann. Hum. Genet. 2010, 74:97-109.
11. Forno L.S. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 1996, 55:259-272.
12. Fung H.C., Scholz S., Matarin M., Simon-Sanchez J., Hernandez D., Britton A., Gibbs J.R., Langefeld C., Stiegert M.L., Schymick J., Okun M.S., Mandel R.J., Fernandez H.H., Foote K.D., Rodriguez R.L., Peckham E., De Vrieze F.W., Gwinn-Hardy K., Hardy J.A., Singleton A. Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol. 2006, 5:911-916.
13. Healy D.G., Abou-Sleiman P.M., Casas J.P., Ahmadi K.R., Lynch T., Gandhi S., Muqit M.M., Foltynie T., Barker R., Bhatia K.P., Quinn N.P., Lees A.J., Gibson J.M., Holton J.L., Revesz T., Goldstein D.B., Wood N.W. UCHL-1 is not a Parkinson's disease susceptibility gene. Ann. Neurol. 2006, 59:627-633.
14. Jellinger K.A. Recent developments in the pathology of Parkinson's disease. J. Neural Transm. 2002, 347-376.
15. Kim J.H., Park M., Yang S.Y., Jeong B.S., Yoo H.J., Kim J.W., Chung J.H., Kim S.A. Association study of polymorphisms in N-methyl-d-aspartate receptor 2B subunits (GRIN2B) gene with Korean alcoholism. Neurosci. Res. 2006, 56:220-223.
16. Kristofikova Z., Stastny F., Bubenikova V., Druga R., Klaschka J., Spaniel F. Age- and sex-dependent laterality of rat hippocampal cholinergic system in relation to animal models of neurodevelopmental and neurodegenerative disorders. Neurochem. Res. 2004, 29:671-680.
17. Liou Y.J., Wang Y.C., Chen J.Y., Bai Y.M., Lin C.C., Liao D.L., Chen T.T., Chen M.L., Mo G.H., Lai I.C. Association analysis of polymorphisms in the N-methyl-d-aspartate (NMDA) receptor subunit 2B (GRIN2B) gene and tardive dyskinesia in schizophrenia. Psychiatry Res. 2007, 153:271-275.
18. Mandel S., Grunblatt E., Maor G., Youdim M.B. Early and late gene changes in MPTP mice model of Parkinson's disease employing cDNA microarray. Neurochem. Res. 2002, 27:1231-1243.
19. Marti M., Mela F., Bianchi C., Beani L., Morari M. Striatal dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors. J. Neurochem. 2002, 83:635-644.
20. Monyer H., Sprengel R., Schoepfer R., Herb A., Higuchi M., Lomeli H., Burnashev N., Sakmann B., Seeburg P.H. Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science 1992, 256:1217-1221.
21. Myhrer T. Adverse psychological impact, glutamatergic dysfunction, and risk factors for Alzheimer's disease, Neurosci. Biobehav. Rev. 1998, 23:131-139.
22. Nash J.E., Ravenscroft P., McGuire S., Crossman A.R., Menniti F.S., Brotchie J.M. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease. Exp. Neurol. 2004, 188:471-479.
23. Ohtsuki T., Sakurai K., Dou H., Toru M., Yamakawa-Kobayashi K., Arinami T. Mutation analysis of the NMDAR2B (GRIN2B) gene in schizophrenia. Mol. Psychiatry 2001, 6:211-216.
24. Olney J.W. Excitotoxic amino acids and neuropsychiatric disorders. Ann. Rev. Pharmacol. Toxicol. 1990, 30:47-71.
25. Pankratz N., Wilk J.B., Latourelle J.C., DeStefano A.L., Halter C., Pugh E.W., Doheny K.F., Gusella J.F., Nichols W.C., Foroud T., Myers R.H. Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum. Genet. 2009, 124:593-605.
26. Plaitakis A., Shashidharan P. Glutamate transport and metabolism in dopaminergic neurons of substantia nigra: implications for the pathogenesis of Parkinson's disease. J. Neurol. 2000, 247(Suppl 2):II25-II35.
27. Rylander D., Recchia A., Mela F., Dekundy A., Danysz W., Cenci M.A. Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J. Pharmacol. Exp. Ther. 2009, 330:227-235.
28. Satake W., Nakabayashi Y., Mizuta I., Hirota Y., Ito C., Kubo M., Kawaguchi T., Tsunoda T., Watanabe M., Takeda A., Tomiyama H., Nakashima K., Hasegawa K., Obata F., Yoshikawa T., Kawakami H., Sakoda S., Yamamoto M., Hattori N., Murata M., Nakamura Y., Toda T. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet. 2009, 41:1303-1307.
29. Satoh J., Kuroda Y. A polymorphic variation of serine to tyrosine at codon 18 in the ubiquitin C-terminal hydrolase-L1 gene is associated with a reduced risk of sporadic Parkinson's disease in a Japanese population. J. Neurol. Sci. 2001, 189:113-117.
30. Seripa D., Matera M.G., Franceschi M., Bizzarro A., Paris F., Cascavilla L., Rinaldi M., Panza F., Solfrizzi V., Daniele A., Masullo C., Dallapiccola B., Pilotto A. Association analysis of GRIN2B, encoding N-methyl-d-aspartate receptor 2B subunit, and Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2008, 25:287-292.
31. Simon-Sanchez J., Schulte C., Bras J.M., Sharma M., Gibbs J.R., Berg D., Paisan-Ruiz C., Lichtner P., Scholz S.W., Hernandez D.G., Kruger R., Federoff M., Klein C., Goate A., Perlmutter J., Bonin M., Nalls M.A., Illig T., Gieger C., Houlden H., Steffens M., Okun M.S., Racette B.A., Cookson M.R., Foote K.D., Fernandez H.H., Traynor B.J., Schreiber S., Arepalli S., Zonozi R., Gwinn K., van der Brug M., Lopez G., Chanock S.J., Schatzkin A., Park Y., Hollenbeck A., Gao J., Huang X., Wood N.W., Lorenz D., Deuschl G., Chen H., Riess O., Hardy J.A., Singleton A.B., Gasser T. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 2009, 41:1308-1312.
32. Srinivasan B.S., Doostzadeh J., Absalan F., Mohandessi S., Jalili R., Bigdeli S., Wang J., Mahadevan J., Lee C.L., Davis R.W., William Langston J., Ronaghi M. Whole genome survey of coding SNPs reveals a reproducible pathway determinant of Parkinson disease. Hum. Mutat. 2009, 30:228-238.
33. Tan E.K. The role of common genetic risk variants in Parkinson disease. Clin. Genet. 2007, 72:387-393.
34. Tsai S.J., Liu H.C., Liu T.Y., Cheng C.Y., Hong C.J. Association analysis for genetic variants of the NMDA receptor 2b subunit (GRIN2B) and Parkinson's disease. J. Neural Transmembr. 2002, 109:483-488.
35. Wang H., Shimoji M., Yu S.W., Dawson T.M., Dawson V.L. Apoptosis inducing factor and PARP-mediated injury in the MPTP mouse model of Parkinson's disease. Ann. N. Y. Acad. Sci. 2003, 991:132-139.